OMARINI, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.427
EU - Europa 3.783
AS - Asia 1.398
AF - Africa 31
SA - Sud America 31
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 10
Totale 10.707
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.387
IT - Italia 1.127
IE - Irlanda 821
GB - Regno Unito 660
CN - Cina 379
SG - Singapore 360
DE - Germania 318
SE - Svezia 318
HK - Hong Kong 245
FR - Francia 113
FI - Finlandia 90
UA - Ucraina 88
IN - India 67
TR - Turchia 65
BG - Bulgaria 58
ID - Indonesia 56
VN - Vietnam 46
JP - Giappone 36
CA - Canada 35
TW - Taiwan 35
LT - Lituania 33
IQ - Iraq 28
BE - Belgio 27
AU - Australia 24
MY - Malesia 23
CZ - Repubblica Ceca 22
EG - Egitto 21
IR - Iran 17
NL - Olanda 16
BR - Brasile 14
ES - Italia 13
PL - Polonia 12
RO - Romania 12
RU - Federazione Russa 12
CH - Svizzera 10
EU - Europa 10
KR - Corea 9
CL - Cile 8
PH - Filippine 8
PK - Pakistan 8
AR - Argentina 5
GH - Ghana 5
MT - Malta 5
CR - Costa Rica 4
AL - Albania 3
GR - Grecia 3
IL - Israele 3
IS - Islanda 3
NG - Nigeria 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
BD - Bangladesh 2
DK - Danimarca 2
HR - Croazia 2
KH - Cambogia 2
MK - Macedonia 2
SA - Arabia Saudita 2
SY - Repubblica araba siriana 2
AT - Austria 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CO - Colombia 1
EC - Ecuador 1
ET - Etiopia 1
HU - Ungheria 1
LV - Lettonia 1
MC - Monaco 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
OM - Oman 1
PE - Perù 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
TH - Thailandia 1
VE - Venezuela 1
ZM - Zambia 1
Totale 10.707
Salva come PNG Salva come JPEG
Città #
Dublin 817
Fairfield 636
Chandler 592
Santa Clara 482
Ashburn 468
Southend 420
Woodbridge 294
Singapore 291
Houston 282
Nyköping 259
Seattle 247
Hong Kong 237
Wilmington 228
Ann Arbor 227
Dearborn 215
Cambridge 176
Jacksonville 143
Modena 118
New York 108
Beijing 97
Helsinki 77
San Diego 74
Milan 70
Princeton 60
Fremont 59
Shanghai 58
Sofia 58
Rome 54
Jakarta 52
Redwood City 52
Bologna 50
Eugene 44
Dong Ket 41
Munich 38
Izmir 37
Bremen 33
Enfield 32
London 31
Parma 27
San Giuliano Milanese 26
Falls Church 25
Guangzhou 22
Asyut 21
Baghdad 21
Brussels 20
Tokyo 20
Reggio Emilia 17
Brno 15
Phoenix 15
Banqiao 14
Paris 14
Absecon 13
Boardman 13
Frankfurt am Main 13
Los Angeles 12
Nanjing 12
Norwalk 12
New Taipei 11
Ottawa 11
Padova 11
Des Moines 10
Bergamo 9
Genoa 9
Kunming 9
Palermo 9
Sassuolo 9
Toronto 9
Caprarola 8
Castelvetrano 8
Florence 8
Napoli 8
Turin 8
Bengaluru 7
Chicago 7
San Mateo 7
Santorso 7
Sydney 7
Venezia 7
Amsterdam 6
Cardiff 6
Carpi 6
Dallas 6
Hefei 6
Istanbul 6
Madrid 6
Monza 6
Mumbai 6
Piacenza 6
San Marco 6
Taranto 6
Vernon 6
Angera 5
Angers 5
Bangalore 5
Bari 5
Bomporto 5
Cagliari 5
Changchun 5
Falkenstein 5
Longiano 5
Totale 7.891
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 401
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 277
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 262
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 260
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. 245
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 230
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 229
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 225
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 215
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 210
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 209
Immune characterization of breast cancer metastases: prognostic implications. 204
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 202
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 202
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 201
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 200
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 199
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 198
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 197
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 196
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 196
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 192
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE​ 184
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 174
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 174
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 174
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 164
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 160
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 157
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 157
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 156
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 156
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 155
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 152
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 149
Lapatinib and renal impairment: a case report 148
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 148
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 141
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 140
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 139
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 139
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 134
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. 133
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 131
The Role of Exosomes in Breast Cancer Diagnosis. 129
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). 124
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 124
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 123
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 122
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 120
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 120
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 117
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 116
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis 111
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! 110
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 106
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges 103
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 102
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 99
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 79
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis. 78
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 65
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist 60
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 57
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 53
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 47
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affectclinical outcome of metastatic breast cancer patients 47
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 42
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 38
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 35
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 32
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 29
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 27
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 26
TDM-1 efficacy in trastuzumabpertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 23
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 17
Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature 17
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments 16
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer 12
Totale 10.841
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.862
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.862
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.131 0 0 0 0 156 243 260 128 140 75 80 49
2020/20211.591 149 100 75 125 183 129 70 180 102 195 124 159
2021/20221.368 77 147 117 58 51 110 63 71 131 126 251 166
2022/20232.647 191 266 146 186 174 202 47 156 960 50 168 101
2023/20241.429 75 65 102 138 175 130 160 211 54 64 102 153
2024/20251.236 141 53 127 268 647 0 0 0 0 0 0 0
Totale 10.841